Peroxisome proliferator-activated receptor γ (PPARγ) is expressed in a variety of cancer cells. The addition of ligand activates the receptor by inducing a conformational change in the receptor, which can be recapitulated by mutation.
Introduction
The peroxisome proliferator-activated receptors (PPAR) are ligand-activated nuclear receptors that include PPARα, PPARγ, and PPARδ (1) . PPARγ, originally cloned as a transcription factor involved in fat cell differentiation (2) , is activated by endogenous ligands, such as fatty acids produced by sterol response element binding protein 1 and fatty acid synthase pathway (3) and synthetic ligands including the thiazolidinediones. Viral transduction of the murine liver with PPARγ induces hepatic steatosis (4) . This differentiation function of PPARγ is antagonized in cultured cells and in vivo by endogenous levels of cyclin D1 (5) . PPARγ regulates expression of secreted proteins, such as ACRP30 (6) , which in turn may affect heterotypic signaling from nearby cells.
It is estimated that at least 2 million patients take antidiabetic drugs that function as PPARγ ligands. Understanding the role of this receptor, including its possible role in cancer, is therefore important. Independent lines of evidence support a role for PPARγ to either inhibit or promote tumorigenesis. In studies of N-nitrosomethylurea-induced mammary tumorigenesis in rats, PPARγ ligands prevented tumor initiation (7) and 7,12-dimethylbenz(a) anthracene-induced mammary tumorigenesis was inhibited by a synthetic ligand, troglitazone (8) . PPARγ is expressed in breast, prostate, and colonic epithelia and addition of ligands to cultured cancer cell lines derived from these tissues inhibits cellular proliferation (9) (10) (11) (12) (13) . Heterozygous mutations of PPARγ have been detected in >80% of patients with colon cancer (14) and chromosomal translocation between PAX8 and PPARγ in follicular thyroid cancer enhanced cellular proliferation (15) .
In contrast with these findings, several studies suggest that PPARγ activation may enhance tumor growth. PPARγ ligands increased polyp numbers in the Apc Min model of familial adenomatosis (16, 17) and PPARγ inhibits β-catenin abundance only in the presence of wild-type APC (17) , raising the possibility that the genetic environment of the host may determine the outcome of PPARγ activation. PPARγ ligands may function independently of the PPARγ receptor with growth inhibition shown in cells lacking PPARγ (18) (19) (20) . To determine the role of the PPARγ and avoid the potential spurious effect of receptor-independent functions, a constitutively active PPARγ (PγCA) was generated, which selectively activated a PPARγ response element without regulating other nuclear receptors. When targeted to mammary epithelium, PγCA collaborated in mammary oncogenesis with polyoma middle T antigen (21) .
Human breast cancer is associated with ErbB2 amplification or overexpression in >30% of patients. Although PPARγ is reduced in ErbB2-induced tumor, the role of PPARγ in growth control of ErbB2-induced tumorigenesis is poorly understood. Herein, we show that PPARγ enhanced ErbB2-induced mammary tumorigenesis in vivo. PγCA promoted tumor angiogenesis through induction of the proangiogenic factor Angptl4. Genome-wide expression profiling identified Angptl4 and Wnt5a as targets of PPARγ. Angptl4 promoted migration of vascular endothelial cells and immunodepletion of Angptl4 diminished the effect of PγCA in promoting cellular migration. Thus, activated PPARγ enhances angiogenesis and tumor growth in vivo. As PPARγ-activating ligands are widely used to treat diabetes, a careful further analysis of breast cancer risk may be warranted.
Materials and Methods
Mice. All animal experiments were done following animal protocols that had been approved by the Institutional Animal Care and Use Committee at Thomas Jefferson University.
Cell culture. Human embryonic kidney 293T was maintained in DMEM containing penicillin and streptomycin (100 mg of each per 1 liter) and supplemented with 10% fetal bovine serum (5) . MCF10A and MCF10A transformed with oncogene NeuT (MCF10A/NeuT) were cultured in DMEM/F-12 (50:50) supplemented with 5% horse serum, 5% fetal bovine serum, insulin (10 μg/mL), epidermal growth factor (20 ng/mL), hydrocortisone (0.5 μg/mL), and cholera toxin (100 ng/mL). Human umbilical vein endothelial cells (HUVEC) were purchased from Lifeline Cell Technology and maintained in VascuLife Basal Medium Supplemented with SMC LifeFactors. All cells were cultured in humidified atmosphere with 5% CO 2 at 37°C.
Plasmids. pCMX-mPPARγ1 was a gift from Dr. C. Glass. The cDNA of mouse PPARγ was amplified by PCR and subcloned into p3xFLAG CMV10 vector (Sigma) and pACT vector (Promega) to express 3xFLAG-tagged (FLAG-PPARγ) and VP16 fusion protein (PγCA), respectively. The coding region of 3xFLAG-PPARγ1 cDNA or PγCA cDNAs (5) was inserted into the MSCV-IRES-GFP vector at the EcoRI site (blunted) upstream of the IRES driving expression of green fluorescent protein (GFP).
S.c. tumor implantation. The NAFA cells derived from oncogenic MMTV-ErbB2 transgenic mice stably expressing PPARγ or PγCA were implanted by s.c. injection in the flank of female 6-to 8-week-old FVB mice. Comparisons were made for 10 to 15 animals in each group between NAFA/GFP, NAFA/PPARγ, and NAFA/PγCA. The tumor growth rates were examined using serial caliper measurements. The tumor volume was calculated using the equation: (a 2 × b) / 2, where a and b are the length and width of the tumor, respectively. Tumors were weighed at the time of sacrifice. At the completion of the experiments, tumors were excised and weighed and statistical significance of differences in tumor volume was log-transformed and analyzed using a linear mixed model. Separate slope and intercepts were computed for each group (GFP, PPARγ, and PγCA) and then compared across groups using a global test followed by pair-wise comparisons via linear contrasts. Data before day 9 were ignored due to zeroes at day 0 (inability to take logarithms) and an initial nonlinearity/ change in some of the animals' growth patterns before day 9. Thus, the intercept at day 9 is interpretable as initiation of growth and the slope is interpretable as rate of growth. For the models, we report coefficients, confidence intervals (CI) of coefficients, and two-sided P values. Analyses were completed in SAS version 9.1.3.
Western blot. Conditioned cell culture medium was concentrated with Amicon Ultra 10K device (Millipore) and separated by 10% SDS-PAGE and the proteins were transferred to nitrocellulose membrane for Western blot as described previously (22) . The following antibodies were used for Western blot: anti-Angptl4 (Invitrogen) and mouse M2 anti-FLAG antibody (Sigma).
Retrovirus preparation and infection. The MSCV-IRES-GFP retrovirus vector and the vector pSV-ψ-E-MLV that provides ecotropic packaging helper function and infection methods were described previously (23) . Retroviruses were prepared by transient cotransfection of vector expressing PPARγ, PγCA, and empty vector together with the helper viral vector into 293T cells using calcium phosphate precipitation. The retroviral supernatants were harvested 48 h after transfection and filtered through a 0.45 μm filter. Mammary epithelial cells MCF10A, MCF10A/NeuT, or NAFA were incubated with fresh retroviral supernatants in the presence of 8 μg/mL polybrene for 24 h, cultured for a further 48 h, and subjected to fluorescence-activated cell sorting (FACStar Plus; BD Biosciences) to select for cells expressing GFP if infection efficiency was lower than expected (<80% GFP-positive cells). GFP-positive cells were used for subsequent analysis.
Nile Red staining of intracellular lipid. Staining was carried out on living cells. When cells had grown to the desired confluence, dye was added to the cell culture at a final concentration of 100 ng/mL and incubated for a minimum of 5 min. Fluorescent and phase-contrast imaging were collected using the ×20 objective of an Olympus IX-70 laser confocal scanning microscope. Nile Red exhibits red fluorescence.
Immunofluorescent staining. Tumors from PPARγ, PγCA, and GFP vector control group were collected and fixed. The antibodies were directed to von Willebrand factor (vWF; DAKO), c-Kit, CD133, and CD31 (Biocare Medical; ref. 24) . Heat-induced epitope retrieval was done on formalin-fixed and paraffin-embedded sections by incubating the sections in citrate buffer with 5% Tween 20 (pH 6.0) at 100°C for 20 min and allowed to cool for 20 min before staining. The sections were then incubated with 3% hydrogen peroxide diluted in 0.02 mol/L PBS (pH 7.4) for 5 min at room temperature, rinsed in 1× TBS for 15 min, and incubated with normal goat serum (PBS containing 10% normal goat serum and 2% bovine serum albumin) for 30 min at room temperature to block nonspecific antibody binding. The slides were rinsed and incubated with primary antibody diluted to a concentration of 1:500 with PBS containing 2% goat serum overnight at 4°C. The slides were then rinsed as above and incubated with horseradish peroxidase-conjugated secondary antibody according to the manufacturer's protocol (Dako EnVision). The signal was visualized using a Cy3-labeled tyramide amplification system (Perkin-Elmer Life Sciences).
Sections were mounted in aqueous medium containing 4′,6-diamidino-2-phenylindole as a nuclear counterstain (Vector Labs). A negative control was done to ensure the specificity of fluorescent immunostaining by replacing primary antibody with a normal rabbit IgG. Sections were examined with an Olympus BX 61 confocal microscope, and representative areas were were log-transformed and analyzed using a linear mixed model. Separate slope and intercepts were computed for each group (GFP, PPARγ, and PγCA) and then compared across groups using a global test followed by pair-wise comparisons via linear contrasts. Analyses were completed in SAS version 9.1.3, and detailed analysis can be found in Table 1 and Supplementary Fig. S1 .
photographed using ×10 and ×20 objectives. The microvessel density of the tumors was analyzed based on vWF staining as described previously (25) . Vessels were quantified at ×200 using a linear encoded motorized XY stage. At least 20 fields were quantified in four different tumor sections. The number of capillary vessels per square millimeter of tumor tissue was quantified using ×10 eyepieces equipped with 10 × 1 mm by 10 × 1 mm graticule and was expressed as a percentage of area of the grid. For control, 30 fields were analyzed in four different tumor samples. At least 40 fields were counted in three tumor sections for each experimental group, and significance was analyzed using the Student's t test. A difference of P < 0.05 was considered to be statistically significant. All analyses were done with SPSS 11.5 software. Data are expressed as mean ± SE. Microarray analysis. Microarray analysis was conducted as described (26) . Total RNA was isolated from tumors using Trizol and used to probe Affymetrix 430 2.0 arrays. RNA quality was determined by gel electrophoresis. Probe synthesis and hybridization were done according to the manufacturer's manual. Three arrays were used for each condition. Analysis of the arrays was done using the statistical package R statistics package and the limma library of the Bioconductor software package. Arrays were normalized using Robust Multiarray Analysis and the genes were ranked using fold change and T test for differentially expressed genes. These genes were then subjected to hierarchical clustering with "complete" agglomeration and each cluster was further analyzed based on known function of the genes contained in the cluster.
Migration assay. Transwell migration assays were done as described before (25) . Briefly, 4 × 10 4 GFP-positive cells were seeded on 8 μm poresized Transwell filter insert (Costar). After 16 h of incubation at 37°C and 5% CO 2 , cells adherent to the top surface of the filter were removed using a Figure 3 . PγCA induces mammary tumor angiogenesis. A, immunostaining was conducted using antibodies against vWF for microvessel formation. Microvessel density was quantitated showing increased microvessel formation in PγCA group (22 ± 1.5) compared with GFP control or PPARγ groups. B, immunostaining was conducted in tumor samples to detect the expression levels of platelet endothelial cell adhesion molecule-1 (CD31) and CD133 (C). cotton applicator. Cells were fixed with 3.7% formaldehyde and stained with crystal violet, and the numbers of cells on the bottom were counted. Data were from three experiments done in triplicate (mean ± SE).
Results
PγCA induces lipid formation in normal and oncogenetransformed mammary epithelial cells. To examine the effect of PγCA on human breast cancer cellular proliferation, immortal MCF10A cells were transduced with expression vectors encoding either PPARγ or PγCA. Cells were selected by GFP expression from the viral expression vector. MCF10A cells transduced with PPARγ were more polarized and less spread than the vector control cells (Fig. 1A) . PγCA induced a similar less spread morphology. Multiple small oil droplets, which stained positively with Nile Red (Fig. 1A) , were identified in both PPARγ and PγCA transduced cells. MCF10A cells transformed with an activating ErbB2 mutant, NeuT, adopt a spindle-shaped and more polarized morphology (Fig. 1B) . Transduction with PPARγ reduced the polarized morphology of MCF10A/NeuT cells (Fig. 1B) accompanied by the formation of a small number of lipid droplets. PγCA also reduced the polarized fibroblastoid morphology of MCF10A/NeuT cells with a relatively greater abundance of Nile Red-positive oil droplets (Fig. 1B) . The accumulation of oil droplets is consistent with the known ability of liganded PPARγ to induce lipid metabolism in fibroblasts and enhanced transactivation of the PγCA in the absence of ligand.
PγCA promotes tumor growth in vivo. The immortal and transformed MCF10A cells, grown in culture with matrix-rich basement membrane constituents, formed spherical structures in which the outermost layer forms polarized epithelium with the basal surface associating with surrounding basement member proteins and the apical surface pointing inward as shown previously (27) . PγCA expression disorganized the polarized structure of MCF10A and MCF10A/NeuT cells (data not shown). The effect of PγCA on ErbB2-induced tumor was next examined in vivo in immunocompetent animals (Fig. 2) . ErbB2-expressing mammary tumor cells (NAFA) derived from MMTV-ErbB2 (FVB) transgenic mice were implanted into FVB animals. The size of PγCA-expressing tumors was greater than either wild-type PPARγ or GFP control group (Fig. 2A) . Tumor volume was enhanced ∼2-fold by PγCA compared with wild-type PPARγ (Fig. 2B) . Supplementary Figure S1A -C displays the individual animal growth profiles Figure 4 . Gene expression profiling of tumors. A, tumors from PPARγ and PγCA groups were collected when the tumor implantation experiment completed. Total RNA prepared from fresh tumors was used for gene profiling using Affymetrix gene expression array. B, heat map was generated based on the genes differentially regulated by PγCA and PPARγ. C, quantitative reverse transcription-PCR was done to quantitatively measure the mRNA abundance of Angptl4, Fgf1, and Ptn. D, 10 mL of conditioned medium were concentrated to 100 μL. Fifty microliters were used for Western blot to determine the abundance of the secreted form of Angptl4 (top). Ten microliters of medium were separated on 10% SDS-PAGE gel followed by staining the gel with Coomassie blue to show the equal loading (bottom).
(dashed lines) as well as the group-specific linear growth models (solid lines). Supplementary Fig. 1D displays the fitted growth models for all three groups. Table 1 provides the parameter estimates from each of these models in addition to information on statistical comparisons. PPARγ-expressing tumors showed significantly lower initial growth rates than the GFP group (intercept difference = −0.66; P = 0.01; 95% CI = −1.18 to −0.14). PγCA-transduced tumors had significantly lower initial growth rates than GFP-expressing tumors (difference = −0.77; P = 0.003; 95% CI = −1.27 to −0.27). This finding is consistent with our observation that NAFA cells expressing PγCA had decreased proliferation rates compared with the control group (data not shown). The PPARγ-expressing tumor growth rates did not differ from GFP, whereas PγCA-expressing tumors had a significantly higher rate of growth than either GFP (slope = 0.07; P < 0.001; 95% CI = 0.04-0.10) or PPARγ (slope = 0.06; P< 0.001; 95% CI = 0.03-0.09). Collectively, these studies show PγCA promotes ErbB2-induced tumor growth in immunocompetent animals.
PγCA promotes angiogenesis. Growth and formation of capillary blood vessels are essential steps required for sustained tumor growth and metastasis and contribute to cancer progression in vivo. To determine the mechanism(s) through which PγCA enhanced ErbB2-mediated tumor growth in vivo, we analyzed blood vessels located in both the periphery and the interior of tumors. vWF is broadly accepted as a marker for endothelial cells. Immunofluorescent staining using anti-vWF antibody showed increased blood vessel density in PγCA-expressing tumors compared with GFP control tumors. Tumors expressing wild-type PPARγ alone did not affect vWF expression (Fig. 3A) . Immunohistochemistry staining with an antibody against platelet endothelial cell adhesion molecule-1 (also known as CD31; Fig. 3B) showed a similar result. Blood vessels in tumors derived from endothelial progenitor cells (EPC) are characterized by CD133 and c-Kit (28, 29) . Increased expression levels of both CD133 and c-Kit were shown in the PγCA-expressing tumors but not in GFP control or PPARγ-expressing tumors (Fig. 3C) . This finding suggests that circulating EPCs released from the bone marrow may contribute to the increased vasculogenesis in ErbB2-induced tumors expressing active PPARγ. Expression profiling of PPARγ target genes in mammary tumors. To investigate the molecular mechanism(s) by which PγCA regulated angiogenesis/vasculogenesis, a genome-wide expression array analysis was conducted. Total RNA was prepared from extirpated tumors grown in immunocompetent mice. Gene expression profiles were compared between PPARγ and PγCA tumors (Fig. 4) . Gene targets differentially regulated by PγCA convey functions in cell communication, angiogenesis, cell cycle, signal transduction, and cell differentiation. Genes regulated by PγCA in the angiogenesis pathway include angiopoietin-like 4 (Angptl4), fibroblast growth factor 9 (Fgf9), fibroblast growth factor 1 (Fgf1), adrenomedullin (Adm), matrix metallopeptidase 12 (Mmp12), Bcl-2/adenovirus E1B 19-kDa interacting protein 3 (Bnip3), pleiotrophin (Ptn), chemokine (C-X-C motif) ligand 2 (Cxcl2), and vascular endothelial growth factor A (Vegfa; Fig. 4B ). We validated several genes including Angptl4, Fgf1, and Ptn by quantitative reverse transcription-PCR on additional tumor samples (Fig. 4C) . Angptl4 was cloned as a PPARγ target gene and initially termed as PPARγ angiopoietin related and fasting-induced adipose factor according to the nature of how this gene was discovered (30, 31) . We have shown previously that Angptl4 was upregulated in primary culture of mammary epithelial cells transduced with PγCA (32). Angptl4 is a secreted protein that belongs to the family of angiopoietin-like proteins. We further showed that Angptl4 secretion was increased in PγCA transduced NAFA cells compared with PPARγ and vector control (Fig. 4D, top) .
PγCA promotes endothelial cell migration through induction of secreted factors. As PγCA induced the expression of genes governing angiogenesis, we hypothesized that secreted factors were involved. We examined the conditioned medium from PγCA-expressing cells in endothelial cell migration assays. Transwell migration assays were conducted. Conditioned medium was collected from MCF10A/NeuT cells expressing GFP, PPARγ, or PγCA and applied to either the top chamber or the bottom chamber (Fig. 5A ). HUVECs were seeded in the Boyden chamber and the cells migrating across the membrane were stained with crystal blue and counted (Fig. 5B) . When conditioned medium from cells expressing PγCA were added to the bottom chamber, the number of migrating cells compared with GFP and PPARγ groups was significantly increased (Fig. 5B, left) . When HUVECs were seeded in the conditioned medium in the top chamber, the number of cells migrating toward the serum-free medium (in the bottom chamber) was significantly reduced (Fig. 5B, right) . These observations suggest that PγCA expression in breast cancer cells induces secreted factors that promote endothelial cell migration.
Angptl4 mediates PγCA induction of angiogenesis. Angptl4 stimulates endothelial cell growth and tubule formation, which is required for neovascularization and adipose tissue expansion (33) . Angptl4 functions to regulate angiogenesis/vasculogenesis (33) (34) (35) , which contributes to solid tumor growth (35) . As PγCA induced Angptl4 expression and secretion, we determined the role of Angptl4 in PγCA-induced endothelial cell migration. To deplete Angptl4 proteins, the conditioned medium from MCF10A/NeuT/PγCA cell culture was incubated with an Angptl4 antibody conjugated to protein A agarose beads. Conditioned medium depleted of Angptl4 was assessed in HUVEC Transwell migration assays. As we expected, more cells cultured in Angptl4-depleted medium transmigrated to the bottom chamber compared with the IgG control (Fig. 5C ), indicating Angptl4-containing medium is more favorable to endothelial cells. These studies suggest that PγCA induction of Angptl4 in breast cancer cells promotes endothelial cellular migration.
Discussion
The current studies showed that the growth of ErbB2-induced mammary tumors implanted in immunocompetent animals is promoted by an activated PPARγ (PγCA) in contrast with a cytostatic effect of PγCA on cancer cell proliferation in tissue culture. The role of PPARγ in tumorigenesis remains poorly understood in regards to growth inhibition effects in cultured cells and in N-nitrosomethylurea-induced or 7,12-dimethylbenz(a)anthracene-induced mammary tumorigenesis. Genetic removal of one allele of the PPARγ gene predisposes mice to gastric cancer (36) . The tumor implantation analysis showed that early growth initiation by PPARγ and PγCA was significantly lower than the initial growth rate of mammary tumors expressing GFP. These findings are consistent with prior studies in which PPARγ ligands enhanced 7,12-dimethylbenz(a)anthracene-induced rat mammary adenocarcinoma (8) and promoted colonic tumor growth in Apc Min mice fed a high-fat diet (17) . Targeted expression of an activated PPARγ to the mammary gland also enhanced tumorigenesis induced by polyoma middle T antigen (21) . It is not feasible to directly compare the effect of PPARγ ligands with a PPARγ mutant that mimics the ligand-activated state, as some PPARγ ligands may possess receptor-independent functions. However, collectively these studies suggest that activated PPARγ can enhance mammary tumor growth induced by either ErbB2 or polyoma middle T antigen. The molecular mechanisms by which PγCA enhanced mammary tumorigenesis were investigated using gene expression profiling and we identified the induction of a proangiogenic pathway. In a prior study with a similar PPARγ mutant, gene expression analysis identified induction of Wnt signaling (21) . It was proposed that the tumor-promoting effects of active PγCA in the mammary epithelium was due to enhanced Wnt signaling (21) .
PPARγ inhibits angiogenesis in vitro (37) . PPARγ is expressed in endothelial cells and PPARγ ligands, 15-deoxy-Δ12,14-prostaglandin J 2 and thiazolidinedione, inhibit tubular structure formation and proliferation of endothelial cell (HUVEC) in tissue culture (38) . Consistent with our findings, a proangiogenic effect of PPARγ ligands was reported (39, 40) . PPARγ ligands promote angiogenesis via induction of VEGF in cardiac myofibroblasts and human vascular smooth muscle cells but inhibit VEGF-mediated blood vessel formation in a chick chorioallantoic membrane model (41) suggesting cell type-specific effects. The current studies of breast cancer in vivo using genome-wide expression screening showed that PγCA induced the proangiogenic genes VEGFa, Fgf1, Fgf4, and Angptl4. Angptl4 belongs to an angiopoietin-like protein family and is secreted by adipocytes, hepatocytes, the placenta, as well as cancer cells. Although the role of Angptl4 in angiogenesis is controversial, Angptl4 promotes angiogenesis in obesity (33) (34) (35) and contributes to solid tumor growth (35) .
Our studies suggest that PγCA induces the number of EPCs within mammary tumors. Because PPARγ increases hematopoietic cell differentiation toward endothelial lineage (42) , blood vessels in tumors may be derived from EPCs. Downregulation of PPARδ in EPCs reduced prostacyclin biosynthesis and decreased capillary formation in nude mice in vivo (43) . Activation of PPARγ or PPARδ promotes angiogenic progenitor cell differentiation toward endothelial cell lineage and facilitates vasculogenesis by increasing the population of hematopoietic stem cells in bone marrow and EPCs in peripheral blood (42, 44) . Patients with coronary artery disease who received pioglitazone had an increased number of EPCs compared with the placebo group and rosiglitazone increased the number and migratory activity of EPCs in type II diabetic patients (45, 46) .
The value of PPARγ as a potential target for the prevention and treatment of cancer using differentiation-based therapies revealed interesting preliminary observations (47) , in which PPARγ ligand was used to treat human liposarcoma (48) . However, a subsequent phase II trial failed to show an effect of rosiglitazone in liposarcoma (49) or in refractory breast cancer (50) . The spread of obesity and increased prevalence of a sedentary lifestyle has substantially increased the incidence of type II diabetes. PPARγ agonists are increasingly used to enhance insulin sensitivity and improve glucose tolerance and thereby reduce complications, including diabetic neuropathy, cardiovascular disease, and retinopathy with blindness. As the current studies show that a ligand-activated PPARγ mutant promotes ErbB2 oncogene-induced tumorigenesis, further epidemiologic studies are required in patients treated with PPARγ agonists for possible effects on tumor development.
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